At sub-antimicrobial doses, these medications act primarily through anti-inflammatory pathways
Among patients without type 2 diabetes, GLP-1 use was associated with a 34% lower fracture risk for those with osteopenia and 38% lower risk for those with osteoporosis
April 2026: As of April 1, 2026, there are 73 pending lawsuits in MDL 3163 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation , which involves claims against Novo Nordisks Wegovy
10.1016/j.yexcr.2013.05.033 Exp
Eat smaller, more frequent meals This is the single most effective strategy
Unfortunately, most interest in GLP-1 has focused on patentable drug treatments rather than nutritional interventions, so we dont know much about how our GLP-1 production responds to various nutrients in our food